Epicure

Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010.

Gefticip (Gefitinib) 250mg Tablet manufactured by Cipla Limited is a prescription anti-cancer medicine that interferes with the growth and spread of cancer cells in the body.

Votrient is a type of biological therapy called a tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins which act as chemical messengers (enzymes) in cells. There are a number of different tyrosine kinases and they stimulate cancer cells to grow. Generic Pazopanib blocks a number of these proteins and is called a multi tyrosine kinase inhibitor (multi TKI). It stops cancer cells forming blood vessels that they need in order to grow. This is called anti-angiogenesis treatment.

Ibrutinib 140mg is a targeted therapy. It inhibits the function of Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival of malignant B cells. It blocks signals that stimulate malignant B cells to grow and divide uncontrollably. It is not a chemotherapy drug but one of what are termed "targeted therapies."